Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data and AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma and Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2021 / Oct / Raman Spectroscopy Predicts Immunotherapy Response
Pharma and Biopharma Spectroscopy

Raman Spectroscopy Predicts Immunotherapy Response

Raman spectroscopy combined with machine learning predicts non-responders to immunotherapy

By James Strachan 10/25/2021 1 min read

Share

Immunotherapy is changing the way we treat cancer – but not for every patient. The approach is currently only effective for a fraction of patients (sometimes as low as 25 percent), and it can lead to debilitating and sometimes fatal immune-related side effects. This has created an urgent need to find biomarkers that identify non-responders – allowing those patients to avoid unnecessary side effects and explore alternative treatment options.

In response, researchers from Johns Hopkins University used label-free Raman spectroscopy to identify biomolecular changes induced by two immune checkpoint inhibitors in the tumor microenvironment of mouse colon cancers (1). They were able to establish that both levels and spatial distributions of collagen, lipids, and nucleic acids change significantly after immunotherapy – even before changes in tumor size.

"This is the first study that shows the ability of this optical technique to identify early response or resistance to immunotherapy,” said Santosh Paidi, who worked on the research as a mechanical engineering PhD student at Johns Hopkins (2).

Rather than targeting a few suspected molecules, the researchers were interested in a holistic picture of the tumor microenvironment. “That’s because the tumor is not just the malignant cell,” said Ishan Barman, associate professor in mechanical engineering and a co-author of the study (2). “The microenvironment contains a complex combination of the tumor stroma, blood vessels, infiltrating inflammatory cells, and a variety of associated tissue cells. Our idea is to take this approach and systematize it so it can be used by doctors to determine whether immunotherapy will be beneficial for the patient.”

The team used multivariate data analysis techniques to unravel the information from Raman spectra. The multivariate curve resolution-alternating least squares (MCR-ALS) analysis provided promising evidence of spectral differences that can be tied to the compositional constituents of the tumors. The differences were subtle, but statistically significant – and corroborated with proteomics analysis. Paidi’s conclusion? “Combined with machine learning, Raman spectroscopy has the potential to transform clinical methods for predicting therapy response.”

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. SK Paidi et al., Cancer Res, [Online ahead of print] (2021). DOI: 10.1158/0008-5472.CAN-21-1438.
  2. John Hopkins University (2021). Available at: https://bit.ly/3lS7XbL.

About the Author(s)

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

More Articles by James Strachan

False

Advertisement

Recommended

False

Related Content

Loading the Molecular Dice
Pharma and Biopharma
Loading the Molecular Dice

December 12, 2024

2 min read

How a framework for controlling molecular reactions at the atomic scale has potential implications for nanotechnology, pharmaceutical synthesis, and clean energy research

CD-MS: To Megadalton and Beyond
Pharma and Biopharma
CD-MS: To Megadalton and Beyond

October 1, 2024

10 min read

Charge-detection mass spectrometry (CD-MS) has extended the range of MS to gigadalton-sized viruses and polymers; and with a commercial instrument in development and exciting new applications in complex protein mixtures, maturity beckons

New NMR Technique Enables Direct Detection of Molecular Chirality
Pharma and Biopharma
New NMR Technique Enables Direct Detection of Molecular Chirality

October 1, 2024

1 min read

Researchers develop an NMR method to distinguish between enantiomers without the need for chiral agents

Mass Spec Imaging Meets Proteomics
Pharma and Biopharma
Mass Spec Imaging Meets Proteomics

October 2, 2024

2 min read

Researchers combine tissue imaging with proteomics to shed light on the neurotoxic effects associated with HIV medication Efavirenz treatment

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.